These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 14745367)

  • 1. Conference report - breast cancer markers: what next? Highlights from the Annual Meeting of the American Society of Clinical Pathology; September 18-21, 2003; New Orleans, Louisiana.
    Mariani SM
    MedGenMed; 2003 Nov; 5(4):20. PubMed ID: 14745367
    [No Abstract]   [Full Text] [Related]  

  • 2. [Comments on American Society of Clinical Oncology/College of American Pathologists for HER2 testing in breast cancer].
    Gong Y; Xiao CH; Fu L
    Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):795-8. PubMed ID: 20193452
    [No Abstract]   [Full Text] [Related]  

  • 3. HER2 Immunohistochemistry-Guided Targeted Fluorescence In Situ Hybridization Analysis Does Not Help Identify Intratumoral Heterogeneity in Breast Cancer.
    Gulbahce HE; Factor R; Geiersbach K; Downs-Kelly E
    Arch Pathol Lab Med; 2016 Aug; 140(8):741. PubMed ID: 27472230
    [No Abstract]   [Full Text] [Related]  

  • 4. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
    Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
    Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
    Jimenez RE; Wallis T; Tabasczka P; Visscher DW
    Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The quality of Her-2/Neu predictive immunohistochemistry: something FISHy?
    Tubbs RR; Stoler MH
    Mod Pathol; 2000 Jan; 13(1):1-3. PubMed ID: 10658903
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system.
    Hanna WM; Hammond E; Taylor CR; Dabbs DJ; Penault-Llorca F; Bloom KJ; Bilous M; Badve S
    Mod Pathol; 2008 Oct; 21(10):1278-80; author reply 1280-1. PubMed ID: 18813329
    [No Abstract]   [Full Text] [Related]  

  • 8. [The impact of HER2 in pathology].
    Li XH
    Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):793-4. PubMed ID: 20193451
    [No Abstract]   [Full Text] [Related]  

  • 9. HER 2 status in invasive breast cancer: immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization.
    Shirsat HS; Epari S; Shet T; Bagal R; Hawaldar R; Desai SB
    Indian J Pathol Microbiol; 2012; 55(2):175-9. PubMed ID: 22771638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conference report - magic markers for the diagnosis of thyroid carcinomas? Highlights from the Annual Meeting of the American Society of Clinical Pathology; September 18-21, 2003; New Orleans, Louisiana.
    Mariani SM
    MedGenMed; 2003 Oct; 5(4):9. PubMed ID: 14745356
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
    Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
    Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
    Guo L; Yuan P; Zhang J; Ling Y; Li W; Zhao B; Ying J; Xuan L
    Breast Cancer Res Treat; 2017 Nov; 166(1):77-84. PubMed ID: 28712009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Japanese Breast Cancer Society clinical practice guidelines for pathological diagnosis of breast cancer, 2015 edition.
    Horii R; Honma N; Ogiya A; Kozuka Y; Yoshida K; Yoshida M; Horiguchi S; Ito Y; Mukai H
    Breast Cancer; 2016 May; 23(3):391-9. PubMed ID: 26914491
    [No Abstract]   [Full Text] [Related]  

  • 14. Correspondence re: Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000;13:37-45.
    Hugh J; Barley R; Dabbagh L
    Mod Pathol; 2001 Mar; 14(3):263. PubMed ID: 11266538
    [No Abstract]   [Full Text] [Related]  

  • 15. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 assessment by silver in situ hybridization: where are we now?
    Sanguedolce F; Bufo P
    Expert Rev Mol Diagn; 2015 Mar; 15(3):385-98. PubMed ID: 25578771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Testing in Breast Cancer: Current Status and Future Directions.
    Sun L; Wu A; Bean GR; Hagemann IS; Lin CY
    J Mol Diagn; 2021 Nov; 23(11):1422-1432. PubMed ID: 34454106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
    Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
    Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New challenges of HER2 testing in breast cancer].
    Yang F; Yang WT; Bu H
    Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):289-92. PubMed ID: 22883664
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH.
    Li-Ning-T E; Ronchetti R; Torres-Cabala C; Merino MJ
    Int J Surg Pathol; 2005 Oct; 13(4):343-51. PubMed ID: 16273190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.